GlaxoSmithKline plc (GSK) (LSE/NYSE:GSK) is gearing up for the demerger of its consumer healthcare business, which it anticipates will be complicated in July. The company announced that it had enlisted six new directors to the designate board of the spinoff, which will be known as Haleon. In addition to Sir Dave Lewis, whom the GSK named…